回盛生物(300871) - 2022 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥397 million, a decrease of 25.89% compared to ¥535 million in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥6.51 million, down 93.57% from ¥101 million in the previous year[22]. - The net cash flow from operating activities decreased by 58.34% to approximately ¥25.81 million, compared to ¥61.97 million in the same period last year[23]. - The basic earnings per share for the first half of 2022 was ¥0.04, a decline of 93.44% from ¥0.61 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was approximately ¥1.38 million, a decrease of 98.55% from ¥94.95 million in the same period last year[23]. - The company achieved operating revenue of ¥397,018,762.74, a decrease of 25.89% compared to the previous year[44]. - The net profit attributable to shareholders was ¥6,512,643.75, down 93.57% year-on-year[44]. - The decline in revenue was primarily due to the continued downturn in the downstream breeding industry, which affected the scale of breeding and the usage of veterinary drugs[44]. - Operating profit for the first half of 2022 was CNY 10,365,515.08, down from CNY 118,198,274.68 in the first half of 2021[196]. - Net profit for the first half of 2022 was CNY 6,512,643.75, a significant decline from CNY 101,328,223.25 in the first half of 2021, representing a decrease of approximately 94%[197]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥2.68 billion, a decrease of 2.19% from ¥2.74 billion at the end of the previous year[23]. - The net assets attributable to shareholders decreased by 3.29% to approximately ¥1.57 billion, compared to ¥1.62 billion at the end of the previous year[23]. - Total liabilities amounted to 1,116.09 million, a slight decrease from 1,122.81 million at the end of the previous year[192]. - The company's asset-liability ratio at the end of the reporting period was 41.62%, an increase of 0.67% compared to the end of the previous year[184]. - Total assets as of June 30, 2022, amounted to CNY 2,375,493,122.08, slightly down from CNY 2,392,531,740.25 at the beginning of the year[195]. - Total liabilities increased to CNY 857,517,112.54 as of June 30, 2022, compared to CNY 827,779,576.09 at the start of the year[195]. Research and Development - The company has established a research institute in collaboration with Huazhong Agricultural University, focusing on innovative drug development and clinical solutions[39]. - Research and development expenses increased by 16.79% to CNY 17,680,760.33, reflecting the company's commitment to innovation[58]. - Research and development expenses for the first half of 2022 were CNY 17,680,760.33, an increase from CNY 15,138,572.29 in the same period of 2021[196]. Product Development and Market Strategy - The company has obtained 142 veterinary drug approval numbers as of June 2022, focusing on pig medications while expanding into poultry, aquaculture, and pet pharmaceuticals[32]. - Revenue from poultry products increased by 3.29% and from aquaculture products by 1.96%, indicating a diversification strategy to mitigate cyclical fluctuations in the pig farming industry[33]. - The company successfully launched the fourth-generation animal-specific antibiotic, Tylosin Injection, and improved the fermentation process of Tylvalosin, increasing efficacy by 4.5% and average yield by 6.7% compared to 2021[33]. - The company has launched 11 pet health products and 2 pet medications, expanding its product offerings in the pet care market[33]. - The company aims to enhance its customer coverage and penetration in the pig medicine sector while expanding into other areas such as poultry and aquaculture to mitigate risks from the pig cycle[92]. Financial Management and Investments - The company reported a significant increase in financial expenses by 173.44% to CNY 2,829,847.73, mainly due to the accrual of convertible bond interest[58]. - The total amount of funds raised by the company is RMB 154,001.15 million, with RMB 42,542.20 million invested during the reporting period[72]. - The company made a significant investment of CNY 10,000,000.00 in Hubei Animal Health Technology Development Co., Ltd., acquiring a 100% stake[68]. - The company has committed to various projects with a total investment of RMB 129,000 million, of which RMB 127,929.90 million has been invested as of the reporting period[80]. Corporate Governance and Compliance - The company has not reported any significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[123]. - The company has not engaged in any major related party transactions during the reporting period, ensuring transparency and compliance[126]. - The company has not experienced any non-operating fund occupation by major shareholders or related parties during the reporting period, reflecting financial integrity[118]. - The company has adhered to all relevant environmental regulations and is actively working towards sustainable development[114]. Shareholder Information - The major shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 49.86% of the shares, totaling 82,800,000 shares, which are subject to a 36-month lock-up period[163]. - The total number of shareholders at the end of the reporting period was not specified, but significant changes in shareholding were noted among major shareholders[163]. - The company’s shareholding structure showed a slight decrease in the proportion of restricted shares from 50.10% to 50.04%[149]. Future Outlook - The company’s future outlook includes maintaining its current credit rating and managing its restricted shares effectively[160]. - The company plans to strengthen project management to ensure timely production of fundraising projects and actively expand the market to increase product market share[99].